StockWatch
·
Pharmaceuticals
Quarterly Result29 May 2026, 01:47 am

Ind-Swift Board Approves Q4 & FY26 Audited Financial Results

AI Summary

Ind-Swift Laboratories Ltd.'s Board of Directors, at its meeting on May 28, 2026, approved the audited financial results for the fourth quarter and the full financial year ended March 31, 2026. These results, presented on both standalone and consolidated bases, include the Statement of Profit & Loss, Statement of Assets & Liabilities, and Statement of Cash Flow. The financial statements were reviewed by the Audit Committee and audited by M/s. Rattan Kaur & Associates. Additionally, the Board re-appointed M/s. V. Kumar & Associates as Cost Auditors for the financial year 2026-27.

Key Highlights

  • Board approved audited financial results for Q4 and FY ended March 31, 2026.
  • Results include standalone and consolidated financial statements.
  • M/s. Rattan Kaur & Associates audited the financial results.
  • M/s. V. Kumar & Associates re-appointed as Cost Auditors for FY2026-27.